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Abstract
Background—Expedited partner therapy (EPT) is a potential partner treatment strategy. 
Significant efforts have been devoted to policies intended to facilitate its practice. However, few 
studies have attempted to evaluate these policies.
Methods—We used data on interviewed gonorrhea cases from 12 sites in the STD Surveillance 
Network (SSuN) in 2010 (n=3,404). Patients reported whether they had received EPT. We coded 
state laws relevant to EPT for gonorrhea using Westlaw legal research database, and the general 
legal status of EPT in SSuN sites from CDC’s website in 2010. We also coded policy statements 
by medical and other boards. We used chi-squares to compare receipt of EPT by legal/policy 
variables, patient characteristics and provider type. Variables significant at p<.10 in bivariate 
analyses were included in a logistic regression model.
Results—Overall, 9.5% of 2,564 interviewed gonorrhea patients reported receiving EPT for their 
partners. Receipt of EPT was significantly higher where laws and policies authorizing EPT 
existed. Where EPT laws for GC existed and EPT was permissible, 13.3% of patients reported 
receiving EPT as compared to 5.4% where there were no EPT laws and EPT was permissible, and 
1.0% where there were no EPT laws and EPT was potentially allowable (p<.01). EPT was higher 
where professional boards had policy statements supporting EPT (p<.01). Receipt of EPT did not 
differ by most patient characteristics or provider type. Policy-related findings were similar in 
adjusted analyses.
Conclusions—EPT laws and policies were associated with higher reports of receipt of EPT 
among interviewed gonorrhea cases.
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Expedited partner therapy (EPT) is a partner management technique where medications or 
prescriptions are provided to the partner of a patient who tests positive for chlamydia or 
gonorrhea without physical examination of the partner. EPT can reduce chlamydia and 
gonorrhea reinfection [1–4] and is recommended by the Centers for Disease Control and 
Prevention (CDC) and other medical and legal organizations. [5–8] Given the effectiveness 
of EPT in reducing sexually transmitted disease (STD) reinfections and the low risk of side 
effects associated with its use [9], policy efforts have focused on facilitating its practice. To 
serve as a resource for providers, Hodge and colleagues analyzed state laws and policies 
relevant to EPT, categorizing the probable legal status of EPT for treating any STD in each 
state as: permissible, potentially allowable, or prohibited. [10] The primary factors 
considered were state statutes (laws passed by the legislature), regulations (promulgated by 
state departments of health or professional licensure boards), and policy statements by state 
professional licensure boards supporting its practice. This resulted in a “comparative 
snapshot of legal provisions that may highlight legislative, regulatory, judicial laws and 
policies concerning EPT.” [11]
Research has evaluated various aspects of EPT. One study found that EPT is routinely 
utilized by family planning providers in California, and that the vast majority of these 
providers feel that it improves care. [12] Additionally, rates of partner treatment are higher 
for both concurrent treatment visits (patient and partner treated concurrently) and EPT as 
compared to standard patient referral. [13] EPT is cost-effective in certain situations [14], 
and changes to clinic policies requiring documentation of EPT have been shown to increase 
EPT’s acceptance. [15] Lastly, provider knowledge of EPT is associated with higher rates of 
practice, yet practice is inhibited by concern for legal liability. [16] Concern for liability 
exists because EPT involves prescribing and dispensing medications to individuals who 
have not been physically examined by a healthcare provider. Potential legal actions include 
medical malpractice lawsuits from individuals or censure from state professional licensure 
boards. [10]
Concern for legal liability is considered one of the primary impediments to the practice of 
EPT [10], and despite policy initiatives intended to clarify its legal status, the effect of these 
laws and policies on the provision of EPT has not been evaluated. Therefore, this study 
investigates the relationship between laws and policies and the practice of EPT by 
comparing the receipt of EPT by gonorrhea patients in Sexually Transmitted Disease 
Surveillance Network (SSuN) participating sites across states of varying legal environments.
MATERIALS AND METHODS
Study Design
We used several sources to assess the relationship between legal and policy aspects of EPT 
and receipt of EPT among reported cases of gonorrhea in the United States (U.S.). For the 
legal and policy variables, we used the Westlaw legal research database (Thompson Reuters, 
New York, NY) and the probable legal status for each state as listed on CDC’s website to 
categorize states. [11] These data were merged with data collected in 2010 from the 12-site 
SSuN, which includes STD programs in health departments in the four U.S. Census regions 
(Figure 1). Each site interviewed a random sample of individuals diagnosed with gonorrhea 
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from cases reported to the health department. Cases were randomly assigned into the sample 
when entered into the surveillance system or were randomly selected from the reported cases 
weekly or biweekly. All sites include at least one county (refer to Figure 1 for a list of 
counties), and cases were eligible for sampling if reported within 30 days of diagnosis. 
Interviews were conducted by telephone and respondents were asked a series of questions 
about their gonorrhea diagnosis.
Measures
We used three measures to assess the legal and policy aspects of EPT as of January 1, 2010: 
1) a combined variable of the general determination of state legal status for EPT as shown 
on CDC’s website (based on legal research conducted by Hodge and colleagues [10]) and 
state laws that explicitly authorize EPT for gonorrhea (law-legal status); 2) state medical 
board statements relevant to EPT; and 3) state non-medical board (e.g., pharmacy board) 
statements relevant to EPT. Using EPT laws specific to gonorrhea from Westlaw, and the 
probable legal status of EPT as displayed on CDC’s website, we coded the primary legal 
variable, law-legal status, into the following categories: 1) has law authorizing EPT for 
gonorrhea and is listed as permissible on CDC website (GC EPT law & CDC permissible); 
2) does not have law authorizing EPT for gonorrhea but is listed as permissible on CDC’s 
website (No GC EPT law & CDC permissible); and 3) does not have law authorizing EPT 
for gonorrhea and is listed as potentially allowable on CDC’s website (No GC EPT law & 
CDC potentially allowable) (Figure 2). We used the legal status of EPT as shown on CDC’s 
website as a measure of the general legal context of EPT for each state. We considered only 
those authorities that carry the force of law (e.g. statutes and regulations) to be “laws” for 
this variable.
We also coded policy variables indicating whether a state medical board or other non-
medical board had released a policy statement that would influence the provision of EPT. 
While these policy statements do not carry the force of law, they are nonetheless 
presumptive of the legal status of EPT in a state and provide a strong indication of the 
likelihood that a board would censure a licensee for practicing EPT. For our purposes, “non-
medical board” meant any professional board or organization other than the entity 
responsible for licensing physicians, including entities such as boards of pharmacy and state 
medical associations. The policy statement variables were coded as 1) yes, statement 
prohibits EPT; 2) yes, statement permits EPT; and 3) no statement influencing EPT. EPT 
laws and policies did not change during the study period in any SSuN site.
Our outcome of interest was receipt of EPT. As part of the SSuN interviews, gonorrhea 
patients were asked if they were given medication or a prescription for their sex partners 
using the following response options: 1) no; 2) no, partner(s) was already treated; and 3) yes. 
Respondents who reported that their partner(s) was already treated were considered 
ineligible for EPT; therefore, our final outcome measure was dichotomous (yes/no). One site 
(San Francisco) used different coding (yes/missing) for this variable that we recoded as 
yes/no; therefore, our estimate of EPT in this site should be interpreted as a minimum 
estimate.
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Additionally, SSuN interviews with gonorrhea patients collected information on patient 
characteristics and provider type. Demographics examined in our analysis included patient 
age (limited to 15–59 year olds), race/ethnicity, education, gender/sexual behavior (women; 
men who have sex with men, MSM; men who have sex with women, MSW), and recent 
incarceration history (past 12 months). Although EPT is not routinely recommended for 
MSM because it might inhibit diagnosis and treatment of coexisting infections [5], our 
purpose was to examine the actual implementation of EPT in areas with different legal 
environments rather than evaluating adherence to CDC guidelines. Therefore, we included 
MSM in our analyses. Additionally, respondents were asked about other STDs (previous 
gonorrhea diagnosis in past 12 months and co-infection with chlamydia during current 
gonorrhea diagnosis), and were asked if they had used crack cocaine or methamphetamines 
in the past 12 months. Respondents reported their number of sex partners in past 3 months 
and were asked several questions about sexual risk in the past 12 months including: had 
anonymous sex partner, met sex partner on internet, exchanged sex for money/drugs, and 
had partner who had been in jail/prison recently. Type of healthcare provider where 
gonorrhea was diagnosed was also included in the analyses.
Statistical Analyses
We used SAS (Release 9.2, SAS Institute, Cary, NC) for analyses. Specifically, the 
SURVEY procedures were used to 1) adjust and account for the complex sample design 
(e.g., clustering by county) and 2) weight data for site sampling fraction and non-response 
(by age, gender, provider type). Our law-legal status variable was highly correlated with our 
two policy variables (policies were included in the general legal status displayed on CDC’s 
website); therefore, we assessed the relationship between these variables and our outcome 
separately. We used chi-square tests for bivariate analyses. Variables significant at p<.10 in 
bivariates were included in an adjusted logistic regression model. We conducted two post-
hoc analyses excluding MSM and Washington (state-wide effort to promote EPT) 
separately, to see if our findings were the same without either group. Finally, in the seven 
SSuN sites that did not have a law authorizing EPT for gonorrhea, we used the chi-square 
test of independence to assess the relationship of each policy variable (state medical board 
and other non-medical board policy statement) to the receipt of EPT. These estimates were 
unstable (relative standard errors were > 30%); therefore, we did not include these variables 
in adjusted models.
RESULTS
In 2010, 3,404 interviews with selected gonorrhea patients were completed with a response 
rate of 39%. Among the sample, 2,564 patients responded to the receipt of EPT question and 
were considered eligible to receive EPT. Overall, 9.5% of eligible gonorrhea patients 
reported receiving EPT for their sex partners. Receipt of EPT was highest in Washington 
state where 43.8% of eligible gonorrhea patients reported receipt of EPT and lowest in 
Connecticut where no eligible gonorrhea patients reported receipt of EPT. Five sites 
reported receipt of EPT by less than 5% of gonorrhea patients; the remaining five reported 
receipt by 10–20% of gonorrhea patients (Figure 1).
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The law-legal status variable was significantly associated with the receipt of EPT (p<.01) 
(Table 1). EPT was received by gonorrhea patients more often in jurisdictions that have a 
GC EPT law and where EPT is considered permissible (13.3%) than in jurisdictions that do 
not have an EPT law and where EPT is considered permissible (5.4%), as well as in 
jurisdictions that do not have an EPT law and where EPT is considered potentially allowable 
(1.0%). Several demographic variables also met our criteria for inclusion in our adjusted 
model. In terms of race/ethnicity, white gonorrhea patients had the highest reported receipt 
of EPT (12.4%), followed by blacks (9.7%), Hispanics (5.9%), and other racial/ethnic 
groups (14.4%, p=.06). The receipt of EPT also differed based on the gender of the patient’s 
sex partner, with MSM receiving EPT 7.5% of the time, MSW receiving EPT 5.8% of the 
time, and women receiving EPT 13.7% of the time (p<.01). Lastly, patients who had a 
recently incarcerated sex partner (past 12 months) had higher reports of receiving EPT 
(13.7%) than those not having such a partner (8.7%, p=.07).
Among states that do not have a law authorizing EPT for GC, the receipt of EPT differed 
based on state medical board or other non-medical board policy statements relevant to EPT 
(Table 2). In states with medical board policy statements permitting EPT, gonorrhea patients 
received EPT at a significantly higher rate (24.4%) than in states with medical board policy 
statements prohibiting EPT (0%) and states without a medical board policy statement (1.1%, 
p<.01). Similar results were found for non-medical board policy statements. In states with 
non-medical board policy statements permitting EPT, gonorrhea patients received EPT at a 
significantly higher rate (24.4%) than in states with non-medical board policy statements 
prohibiting EPT (3.8%) and states without a non-medical board policy statement (1.0%, 
p<0.1). Washington implemented an extensive state-wide effort to increase EPT uptake 
among providers; therefore, we also examined policy variables excluding this site. The 
significant differences remained (p<.01) but the percentage who received EPT dropped to 
4.5% where state medical and non-medical boards had statements permitting EPT.
Multiple Logistic Regression Models
In adjusted analyses, gonorrhea patients in states that have an EPT law and where EPT is 
considered permissible (adjusted odds ratio [AOR], 23.2 [95% CI, 6.0–89.8]) and states that 
do not have an EPT law but where EPT is considered permissible (AOR, 7.3 [95% CI, 1.7–
30.7]) were more likely to have received EPT than gonorrhea patients in states without a law 
and where EPT is potentially allowable (Table 1). Of the demographic variables included in 
the model, gender of sex partners was the only variable that remained statistically significant 
in adjusted analysis. MSW were less likely to receive EPT than women (AOR, 0.4 [95% CI, 
0.2–0.8]), as were MSM (AOR, 0.3 [95% CI, 0.2–0.70]). Race/ethnicity and having a 
recently incarcerated partner (past 12 months) were not significant in adjusted analyses.
Finally, we conducted two additional analyses to determine if findings were the same when 
separately excluding 1) MSM and 2) Washington (data not shown in tables). When 
excluding MSM, the findings for the law-legal status variable, gender of sex partners, and 
having an incarcerated partner in the past 12 months were similar to results from the overall 
model; however, we found one difference in that non-Hispanic whites (AOR, 2.1 [95% CI, 
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1.1–4.1]) were significantly more likely than non-Hispanic blacks to have received EPT. 
When excluding Washington, the only finding that was not similar to the overall model was 
that gonorrhea patients in states that do not have an EPT law but where EPT is considered 
permissible (AOR, 1.9 [95% CI, 0.5–7.6]) did not differ from patients in sites without a law 
and where EPT is considered potentially allowable.
DISCUSSION
This study suggests that laws and policies authorizing EPT are associated with higher 
reports of receipt of EPT among gonorrhea patients when adjusting for patient and provider 
variables associated with EPT. While this is the first study to evaluate the relationship 
between laws and EPT by comparing uptake across states of varying legal environments, our 
findings are consistent with evaluations of EPT uptake within jurisdictions that have laws 
authorizing EPT. [12] Potential explanations include the possibility that laws authorizing 
EPT may diminish provider concern for legal liability, as such laws explicitly make the 
practice of EPT legal within a jurisdiction. Uptake is also higher in jurisdictions where EPT 
is deemed permissible versus those in which it is potentially allowable, notwithstanding the 
existence of an EPT law. However, in adjusted analyses, these findings were only observed 
when the site with an intensive state-wide effort to promote the use of EPT (Washington) 
was included.
This study found that having a law or a regulation authorizing EPT was associated with 
higher receipt of EPT. However, in states where such laws or regulations do not exist, our 
findings suggest that professional licensure board policy statements are related to an 
increase in the receipt of EPT, as the receipt of EPT was significantly higher in states with 
policy statements endorsing EPT, even when excluding Washington. It should be noted, 
however, that board policy statements do not carry the force of law as statutes and 
regulations do; policy statements are nevertheless highly presumptive of boards’ priorities in 
terms of regulating healthcare professionals.
It is worth noting that receipt of EPT was low overall with fewer than 1 in 10 gonorrhea 
patients reporting that they received it. While receipt of EPT for gonorrhea was higher 
within jurisdictions with laws authorizing EPT for gonorrhea, it was still relatively low in 
these areas. Thus, while laws may alleviate provider concerns with dispensing medication 
without a physical examination, other possible barriers to the use of EPT may remain. 
Among providers, awareness of EPT and reimbursement issues may inhibit EPT use even in 
supportive legal environments. Furthermore, technological advancements like electronic 
health records, may optimize the practice of EPT. [15] Finally, it is possible that uptake of 
new strategies may take several years; therefore, future research should examine the time 
since a law took effect and health department and other organizations’ efforts to increase the 
use of EPT.
There are some limitations to our analysis. First, our findings may not be generalizable to 
gonorrhea patients across the U.S. given that only 12 sites participated in SSuN (accounting 
for approximately 20% of U.S. gonorrhea cases), and the response rate was low (39%). 
Additionally, the number of sites produced limited legal environment variation. The second 
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limitation is that this study analyzes the receipt of EPT among gonorrhea patients, yet it has 
been suggested that EPT is more commonly provided to chlamydia patients. This limitation 
was due to the lack of available data on the receipt of EPT for chlamydia; future studies 
should investigate this issue as such data becomes available. Additionally, given increasing 
antimicrobial resistance, in 2012, CDC amended its guidance concerning EPT for gonorrhea 
stating “if a heterosexual partner of a patient cannot be linked to evaluation and treatment in 
a timely fashion, then expedited partner therapy should be considered, using oral 
combination antimicrobial therapy for gonorrhea…”. [17] Thus, the receipt of EPT for 
gonorrhea may have changed since the time of data collection, and concerns regarding 
susceptibility to oral cephalosporins may limit the practice of EPT for gonorrhea moving 
forward. Third, this study is not a randomized controlled trial; causality cannot be inferred 
from our results. Lastly, it is possible that states with providers more receptive to EPT are 
more likely to pass a law. Thus, the receipt of EPT itself could cause a legal environment 
more amendable to EPT, rather than the legal environment facilitating its practice. 
Additionally, it is possible that health departments may more actively promote the use of 
EPT in states that pass laws.
The results of this analysis show that, within our sample, individuals with gonorrhea in 
jurisdictions that have an EPT law, and to a lesser degree, jurisdictions where EPT is 
considered legally permissible, are significantly more likely to receive EPT as a treatment 
option. Similarly, in those jurisdictions without an EPT law, EPT was practiced at a 
significantly higher rate in jurisdictions with a medical or non-medical board that supports 
its practice. For jurisdictions wanting to increase the receipt of EPT, this study suggests that 
laws and policies may be effective options for doing so.
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Based on interviewed gonorrhea cases in the STD Surveillance Network, laws and 
policies authorizing EPT were associated with higher reports of receipt of EPT.
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Figure 1. Receipt of EPT among interviewed gonorrhea patients by SSuN site, 2010. (n=2564)*
Counties sampled by site include: Alabama, Jefferson County (AL); Baltimore, Baltimore 
City (Balt); California, all counties excluding San Francisco County (CA)†; Chicago, Cook 
County (Chic); Colorado, Adams, Arapahoe and Denver counties (CO); Connecticut, 
Hartford and New Haven counties (CT); Louisiana, Orleans Parish (LA); Philadelphia, 
Philadelphia County (Phil); New York City, Kings, Queens, Bronx, Richmond, New York 
counties (NYC); San Francisco, San Francisco County (SF); Virginia, Chesterfield and 
Henrico counties and Richmond City (VA); Washington, all counties (WA).
*Data were weighted for site sampling fraction and non-response.
†California and San Francisco are independently funded and operated SSuN sites.
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Figure 2. Legal status of EPT for gonorrhea by SSuN site as of January 1, 2010
This map represents a combination of the legal status of EPT displayed on CDC’s website 
and whether a state had a law explicitly legalizing EPT for gonorrhea. This study examined 
data from Baltimore City only. For legibility, the coding used for Maryland is based on 
Baltimore law. Furthermore, Baltimore’s laws apply only to STD clinics within Baltimore 
City.
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Table 1
Receipt of EPT among interviewed gonorrhea cases by site legal status, patient characteristics and provider 
type (n=2564): Bivariate and adjusted analyses
Correlates
Bivariate Analyses
Adjusted OR (95% CI)Unweighted N Weighted % (SE) P value
Legal/policy issues
Site law-legal status <.01
 GC EPT law & CDC permissible 1201 13.3% (3.3) 23.2 (6.0–89.8)
 No GC EPT law & CDC permissible 984 5.4% (2.1) 7.3 (1.7–30.7)
 No GC EPT law & CDC potentially allowable 379 1.0% (0.5) 1.0
Patient characteristics
Age (years) .94 --
 15–19 597 8.0% (3.2)
 20–24 810 9.7% (2.7)
 25–34 691 8.9% (2.0)
 35–59 400 8.4% (2.9)
Race/ethnicity .06
 White (non-Hispanic) 495 12.4% (2.7) 1.4 (0.8–2.5)
 Black (non-Hispanic) 1414 9.7% (2.6) 1.0
 Hispanic 458 5.9% (2.1) 0.5 (0.3–1.1)
 Other 152 14.4% (4.1) 1.5 (0.7–2.9)
Education level .27 --
 < high school 551 9.0% (3.4)
 High school/GED 809 7.2% (2.1)
 Some college 681 10.3% (2.6)
 College or higher 315 5.3% (2.1)
Incarcerated (past 12 months) .96 --
 No 2266 9.3% (2.0)
 Yes 253 9.5% (4.0)
Gender/sexual behavior .01 --
Men
 MSM 620 7.5% (2.7) 0.3 (0.2–0.7)
 MSW 734 5.8% (1.9) 0.4 (0.2–0.8)
Women 1190 13.7% (3.2) 1.0
Previous gonorrhea diagnosis (past 12 months) .55 --
 No 2114 8.6% (2.0)
 Yes 286 10.8% (4.4)
Co-infected with chlamydia .76 --
 No 1352 13.0% (3.2)
 Yes 616 12.1% (2.6)
Number of sex partners (past 3 months) .81 --
 1 partner 1184 10.6% (2.8)
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Correlates
Bivariate Analyses
Adjusted OR (95% CI)Unweighted N Weighted % (SE) P value
 2 partners 617 9.1% (3.3)
 3 or more partners 623 8.5% (2.9)
Had anonymous sex partner (past 12 months) .68 --
 No 1936 9.9% (2.5)
 Yes 445 7.7% (4.3)
Met sex partner via Internet (past 12 months) .72 --
 No 1866 7.5% (1.9)
 Yes 330 6.6% (2.9)
Exchanged sex for $/drugs (past 12 months) .73 --
 No 2358 9.5% (2.2)
 Yes 70 8.2% (4.2)
Had recently incarcerated partner (past 12 months) .07
 No 2098 8.7% (2.1) 1.0
 Yes 272 13.7% (4.9) 1.1 (0.6–1.7)
Used crack cocaine (past 12 months) .88 --
 No 2343 9.1% (2.1)
 Yes 81 8.8% (2.9)
Used methamphetamines (past 12 months) .99 --
 No 2323 9.1% (2.1)
 Yes 101 9.1% (4.2)
Provider type .42 --
 STD clinic 716 9.7% (4.0)
 Reproductive health (FP/GYN) 369 15.2% (5.9)
 ER/urgent care 247 7.6% (2.7)
 Hospital other 277 6.2% (2.2)
 HMO/private 394 6.0% (1.6)
 Public/community health center 222 9.0% (3.6)
 Other 252 11.8% (3.6)
Note. GC = gonorrhea. MSM = men who have sex with men. MSW = men who have sex with women. Past 3 months refers to the 3 months prior to 
current gonorrhea diagnosis. Among women, there was no difference in receipt of EPT by pregnancy status. N adjusted analyses = 2323.
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Table 2




Unweighted N Weighted % (SE) P value
All 7 sites (n=1363)
State medical board opinion+ <.01
 Yes, prohibits 0 0
 Yes, permits 448 24.4% (10.1)*
 No 915 1.1% (0.4)*
Other non-medical board opinion† <.01
 Yes, prohibits 115 3.8% (0.8)
 Yes, permits 448 24.4% (10.1)*
 No 800 1.0% (0.4)*
6 sites without a state-wide effort to promote EPT (n=1124)
State medical board opinion† <.01
 Yes, prohibits 0 0
 Yes, permits 209 4.5% (0.5)
 No 915 1.1% (0.4)*
Other non-medical board opinion† <.01
 Yes, prohibits 115 3.8% (0.8)
 Yes, permits 209 4.5% (0.5)
 No 800 1.0% (0.4)*
†
Board rulings defined as “prohibit” did not refer directly to EPT.
*
Estimate is unstable: relative standard error is > 30%.
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